USANA Health Sciences Inc. - 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for USANA Health Sciences Inc. for the period ended April 1, 2006. USANA develops, manufactures, and distributes nutritional and personal care products through a network marketing system (Direct Selling) and provides contract manufacturing services. As of April 1, 2006, the company reported approximately 136,000 active Associates and 73,000 active Preferred Customers worldwide.
Key Financial Metrics
| Metric | Q1 2006 | Q1 2005 |
|---|---|---|
| Net Sales | $89.7 million | $76.6 million |
| Gross Profit | $68.3 million (76.2% margin) | $58.6 million (76.5% margin) |
| Net Earnings | $9.6 million | $8.9 million |
| Diluted EPS | $0.50 | $0.45 |
| Cash from Operations | $15.4 million | $7.5 million |
| Cash & Equivalents (End of Period) | $25.5 million | $22.0 million |
| Long-term Debt | $0 | $0 |
Note: All figures in millions unless otherwise noted. Q1 2006 results include the adoption of SFAS No. 123(R) for equity-based compensation.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 17.1% year-over-year, driven by a 14.3% increase in active Associates and a 10.6% increase in Preferred Customers. The Direct Selling segment grew 16.2%, while Contract Manufacturing grew 50.2% due to backlogged orders.
- Accounting Change: Effective January 1, 2006, the company adopted SFAS No. 123(R), recognizing equity-based compensation expense. This reduced Q1 2006 net earnings by $0.7 million and diluted EPS by $0.03 compared to what would have been reported under the prior method.
- Liquidity: Cash and cash equivalents increased significantly to $25.5 million from $10.6 million at the end of 2005, supported by strong operating cash flows of $15.4 million.
- Segment Margins: Consolidated gross margin decreased slightly to 76.2% due to a higher mix of lower-margin Contract Manufacturing sales. However, Direct Selling margins improved to 78.8% due to lower raw material costs.
Guidance, Outlook, and Risks
- Revenue Guidance: Management expects Q2 2006 consolidated net sales between $92 million and $94 million. Full-year 2006 sales growth is projected between 15% and 20%, contingent on opening a new international market in the second half of the year.
- Earnings Guidance: Q2 2006 diluted EPS is expected to be between $0.51 and $0.53. Full-year 2006 EPS growth is projected at 15-20% excluding equity-based compensation. Equity-based compensation is expected to reduce full-year 2006 diluted EPS by approximately $0.18.
- Capital Expenditures: The company is expanding its corporate headquarters, with a total estimated investment of $13 million. Approximately $8 million is expected to be invested in 2006.
- Risks: Key risks include government scrutiny of network marketing practices (including a proposed FTC rule), reliance on independent Associates, foreign currency fluctuations, and potential delays in international market approvals.
Investor Verification Checklist
- Equity Compensation Impact: Verify the long-term impact of SFAS No. 123(R) on future earnings, as $19.1 million of unrecognized compensation expense remains to be recognized over 2.5 years.
- International Expansion: Monitor the status of the new market launch expected in H2 2006, as the upper end of the revenue guidance depends on this approval.
- Associate Retention: Review trends in active Associate counts and turnover rates, as the business model relies heavily on this network.
- Regulatory Environment: Track the status of the proposed FTC "New Business Opportunity Rule" and its potential effect on compensation plan disclosures.
- Contract Manufacturing Viability: Assess the sustainability of the Contract Manufacturing segment, which currently operates with minimal margins and serves a limited number of external customers.